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Objective: The aim of this study was to immunohistochemically analyse bone resorption
regulators (receptor activator of nuclear factor kappa B ligand [RANKL] and osteoprotegerin
[OPG]), angiogenic index, and myofibroblasts in Gorlin syndrome-related odontogenic
keratocysts (SOKCs) and non-syndrome odontogenic keratocysts (NSOKCs).
Study design: Twenty-two SOKCs, 22 primary NSOKCs, and eight recurrent NSOKCs were
evaluated by immunohistochemistry using anti-RANKL and anti-OPG antibodies. The
angiogenic index was determined by microvessel count (MVC) using anti-CD34 antibody.
Anti-a-smooth muscle actin (a-SMA) antibody was used for the identification of myofibro-
blasts.
Results: Analysis of the expression of RANKL and OPG in the epithelial lining and fibrous
capsule did not reveal significant differences between groups (P > 0.05). In the epithelial
lining, the RANKL/OPG ratio was RANKL < OPG and RANKL = OPG in most primary NSOCKs
(54.5%) and SOKCs (59.1%), respectively (P > 0.05). In the fibrous capsule, the ratio was
RANKL = OPG in most primary (81.8%) and recurrent NSOKCs (75.0%) and in most SOKCs
(45.5%) (P > 0.05). No significant differences in the angiogenic index or number of myofi-
broblasts were observed between primary NSOKCs, recurrent NSOKCs, and SOKCs (P > 0.05).
Conclusions: The present results suggest that differences in the biological behaviour of
SOKCs and NSOKCs may not be related to the expression of RANKL and OPG, to the
RANKL/OPG ratio, to the angiogenic index, or to the number of myofibroblasts in these
lesions.
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Odontogenic keratocysts (OKCs), which have been recently
reclassified by the World Health Organization as benign
neoplasms,1 are distinguished from other odontogenic cysts* Corresponding author at: Universidade Federal do Rio Grande do Nort
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Open access under the Elsevier OA license.by their aggressive biological behaviour, tendency towards
recurrence, and association with nevoid basal cell carcinoma
syndrome or Gorlin syndrome.2,3
OKCs associated with Gorlin syndrome (SOKCs) have been
suggested to present a greater growth and infiltration capacity
and a higher tendency to recur than non-syndrome OKCse, Departamento de Odontologia, Av. Senador Salgado Filho, 1787,
ax: +55 84 3215 4138.
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sis,4,7 oncogenes, tumour suppressor genes,7 extracellular
matrix composition,8 and proteases9,10 support the existence
of a distinct biological behaviour of SOKCs and NSOKCs.Recent
reports have shown that proteins involved in bone remodel-
ing11,12 and angiogenesis,13 as well as myofibroblasts,14,15 play
an important role in the growth and progression of odonto-
genic cysts and tumours. According to some of these studies,
the expression of proteins involved in bone resorption, the
angiogenic index, and the number of myofibroblasts tend to be
higher in lesions with a more aggressive biological behav-
iour.12–14
Bone remodelling is a highly coordinated process that
involves bone resorption mediated by osteoclasts and synthe-
sis of organic matrix mediated by osteoblasts.16,17 Particularly,
three molecules belonging to the tumour necrosis factor
ligand and receptor superfamilies, called receptor activator of
nuclear factor kappa B (RANK), RANK ligand (RANKL) and
osteoprotegerin (OPG), are critical for the control of bone
remodelling17,18 and also play a potential secondary role in
angiogenesis.19,20
Angiogenesis is the formation of new blood vessels from
the preexisting vasculature,21 and it can be evaluated by the
quantification of vessels immunolabeled with antibodies
against endothelial cell epitopes such as CD34.13 The impor-
tance of vascular networks for the development and mainte-
nance of tissues has been demonstrated in many physiological
and pathological processes such as wound healing, arthritis,
and tumour progression.22,23
Myofibroblasts are specialised cells that show a hybrid
phenotype between fibroblasts and smooth muscle cells.15
Due to their contractile features and capacity to synthesise
extracellular matrix components, myofibroblasts have been
implicated in the pathogenesis of fibrocontractive diseases
such as renal fibrosis.24,25 In addition, myofibroblasts seem to
play a role in tumour progression due to their ability to secrete
proteases and cytokines.25,26
In light of these findings, the objective of the present study
was to immunohistochemically analyse bone resorption
regulators (RANKL and OPG), angiogenic index, and myofi-
broblasts in SOKCs and NSOKCs in order to better understand
the differences in the biological behaviour of these lesions.
2. Materials and methods
Fifty-two OKC specimens, including 22 SOKCs, 22 primary
NSOKCs and 8 recurrent NSOKCs, obtained from the Oral
Pathology Departments of the Federal University of Rio Grande
do Norte (UFRN) and of the University of Fortaleza (UNIFOR),
were randomly selected for this study. The size of the sampleTable 1 – Clone, specificity, manufacturer, dilution, antigen re
Clone Specificity Manufacturer 
N-19 RANKL Santa Cruz Biotechnology, Santa Cruz, CA
N-20 OPG Santa Cruz Biotechnology, Santa Cruz, CA
a-sm1 a-SMA Novocastra Laboratories, Benton Lane, NE
QBEnd-10 CD34 Dako, Carpinteria, CA was defined by the number of available institutional archival
cases. In all cases, the histological diagnosis was based on the
second WHO classification.27 All syndrome patients had been
diagnosed according to the criteria proposed by Evans et al.28
and presented multiple OKCs. The patients with sporadic
OKCs had single lesions and had been submitted to clinical
and radiographical assessment to exclude the presence of
other manifestations of Gorlin syndrome. Serial 3-mm thick
sections were cut from the tissue blocks and processed for
immunohistochemical examination. The study was approved
by the Research Ethics Committee of UFRN, Natal, Brazil.
2.1. Immunohistochemistry
The tissue sections were deparaffinised and immersed in 3%
hydrogen peroxide to block endogenous peroxidase activity.
The sections were then washed in phosphate-buffered
saline (PBS). Antigen retrieval, antibody dilution and clone
type for RANKL, OPG, CD34 and a-SMA are shown in Table 1.
After treatment with normal serum, the sections were
incubated with the primary antibodies in a moist chamber.
The sections were then washed twice in PBS and treated
with the labelled streptavidin biotin complex (LSAB + Sys-
tem-HRP; Dako, Carpinteria, CA) at room temperature to
bind the primary antibodies. Peroxidase activity was
visualised by immersing the tissue sections in diamino-
benzidine (Liquid DAB + ; Dako, Carpinteria, CA), which
resulted in a brown reaction product. Finally, the sections
were counterstained with Mayer’s haematoxylin and cover-
slipped. Sections of central giant cell lesion served as
positive control samples for RANKL and OPG. Sections of
lobular capillary hemangioma were used as positive control
for CD34 and a-SMA. Samples treated as described above,
except that the primary antibody was replaced with a
solution of bovine serum albumin in PBS, were used as
negative control.
2.2. Analysis of immunostaining
The tissue sections were examined in a blind fashion by two
observers under an Olympus CX31 light microscope (Olympus
Japan Co., Tokyo, Japan). The immunoexpression of RANKL
and OPG was evaluated both in the epithelial lining and in the
fibrous capsule of OKCs. In the epithelial lining, immunopo-
sitive cells were evaluated semiquantitatively according to an
adaptation of the method used by Nonaka et al.29 The
immunoexpression of RANKL and OPG was classified as
follows at 100 magnification: 0 (10% immunopositive cells),
1 (11–50% immunopositive cells), 2 (51–75% immunopositive
cells), and 3 (>75% immunopositive cells). Next, each case was
assigned to one of the following groups according to thetrieval and incubation of the primary antibodies.
Dilution Antigen retrieval Incubation
 1:200 Citrate, pH 6.0, Pascal, 3 min 18 h
 1:200 Citrate, pH 6.0, Pascal, 3 min 18 h
T 1:50 Citrate, pH 6.0, Pascal, 3 min 60 min
1:50 Tris–EDTA, pH 9.0, Pascal, 3 min 18 h
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L = OPG.
The immunoexpression of RANKL and OPG in the fibrous
capsule of OKCs was evaluated quantitatively. An adaptation
of the method proposed by da Silva et al.12 was used. Tissue
sections were examined by light microscopy to identify five
fields immediately beneath the cystic epithelial lining that
contained the largest number of immunostained cells. The
number of positive and negative cells was determined in each
field at 400 magnification, permitting the calculation of the
percentage of RANKL- and OPG-positive cells in each case. On
the basis of this percentage, the following scores were
assigned to each sample: 0 (10% immunostained cells), 1
(11–50% immunostained cells), 2 (51–75% immunostained
cells), and 3 (>75% immunostained cells).29 Next, each case
was assigned to one of the following groups according to the
RANKL/OPG ratio: RANKL > OPG, RANKL < OPG, and RANK-
L = OPG.
The angiogenic index in SOKCs and NSOKCs was deter-
mined based on the number of anti-CD34-immunoreactive
vessels. Microvessel count (MVC) was performed as described
by Maeda et al.30 Tissue sections were examined by light
microscopy at 100 magnification and five areas immediately
beneath the cystic epithelial lining showing the highest
vascularisation were identified. Vessels were counted in these
five areas of highest vascular density at 200 magnification.
MVC is expressed as the mean number of vessels in these
areas per sample. Single endothelial cells or clusters of these
cells, with or without lumen, were considered to be individual
vessels.
With respect to myofibroblasts, a-SMA-immunopositive
cells were quantified according to an adaptation of the method
proposed by Vered et al.14 Tissue sections were examined by
light microscopy at 100 magnification to identify 10 fields
immediately beneath the cystic epithelial lining that con-
tained the largest number of immunostained cells. In these
fields, a-SMA-positive cells, excluding those surrounding
blood vessels, were counted at 400 magnification and the
total number of positive cells in all 10 fields examined per case
was calculated, permitting the calculation of the mean
number of a-SMA-positive cells per field.
2.3. Statistical analysis
The results obtained were submitted to statistical analysis
using the Statistical Package for the Social Sciences (version
17.0; SPSS Inc., Chicago, IL). The nonparametric Kruskal–
Wallis test was applied to compare the percentage of RANKL-
and OPG-immunopositive cells in the epithelial lining and in
the fibrous capsule between SOKCs, primary NSOKCs, and
recurrent NSOKCs. The chi-square test was used to analyse
the RANKL/OPG ratio in the epithelial lining and fibrous
capsule of SOKCs, primary NSOKCs, and recurrent NSOKCs.
MVC and the number of myofibroblasts was compared
between SOKCs, primary NSOKCs and recurrent NSOKCs by
the nonparametric Kruskal–Wallis test. Spearman’s correla-
tion test was performed to determine possible correlations
between MVC, number of myofibroblasts, and percentage of
RANKL- and OPG-immunopositive cells. For all tests, signifi-
cance level was set at 5% (P < 0.05).3. Results
3.1. Immunoexpression of RANKL and OPG
Analysis of the expression of RANKL and OPG in the epithelial
lining of OKCs revealed cytoplasmic immunoreactivity for
these proteins, with no peculiar pattern of distribution in the
different cell layers. For RANKL, most SOKCs were classified as
score 3 (63.6%) (Fig. 1a), followed by scores 1 (27.3%) and 2
(9.1%). In primary NSOKCs, most cases were classified as score
3 (40.9%), followed by scores 2 (36.4%) and 1 (22.7%) (Fig. 1b).
With respect to recurrent NSOKCs, there was a slight
predominance of cases scored as 2 (50.0%), followed by scores
3 (25.0%) and 1 (25.0%). Statistical analysis revealed no
significant differences between groups (P = 0.408).
Regarding the epithelial expression of OPG, SOKCs showed
a predominance of cases scored as 3 (81.8%), followed by
scores 2 (9.1%), 1 (4.5%) (Fig. 1c), and 0 (4.5%). In primary
NSOKCs, most cases were classified as score 3 (86.4%) (Fig. 1d),
followed by scores 2 (9.1%) and 1 (4.5%). In recurrent NSOKCs,
there was a predominance of cases scored as 3 (62.5%),
followed by scores 1 (25.0%) and 2 (12.5%). The nonparametric
Kruskal–Wallis test showed no significant differences be-
tween groups (P = 0.313).
With respect to the RANKL/OPG ratio in the epithelial
lining, a RANKL < OPG ratio was observed in most primary
NSOKCs (54.5%), whereas most SOKCs presented a RANK-
L = OPG ratio (59.1%). Regarding recurrent NSOKCs, there was
a slight predominance of cases with a RANKL < OPG ratio
(50.0%). Statistical analysis revealed no significant differences
between groups (P = 0.573) (Table 2).
In the fibrous capsule, RANKL and OPG were expressed in
endothelial cells, in fibroblasts (Fig. 1a–d), and in bone
surrounding cells. With respect to the expression of RANKL,
most primary NSOKCs were scored as 3 (54.5%), followed by
scores 2 (40.9%) and 1 (4.5%). In recurrent NSOKCs, most cases
were classified as score 2 (62.5%), followed by score 3 (37.5%). In
SOKCs, there was a predominance of cases scored as 3 (54.5%),
followed by scores 2 (36.4%) and 1 (9.1%). The nonparametric
Kruskal–Wallis test showed no significant differences be-
tween groups (P = 0.805).
Regarding the immunoexpression of OPG in the fibrous
capsule, primary NSOKCs were predominantly classified as
score 3 (63.6%), followed by scores 2 (31.8%) and 1 (4.5%). In
recurrent NSOKCs, most cases were classified as score 2
(62.5%), followed by scores 3 (25.0%) and 1 (12.5%). With respect
to SOKCs, there was a slight predominance of cases scored as 3
(59.1%), followed by score 2 (40.9%). Statistical analysis
revealed no significant differences between groups (P = 0.128).
Analysis of the RANKL/OPG ratio in the fibrous capsule of
primary NSOKCs revealed a predominance of RANKL = OPG
(81.8%). Similarly, most recurrent NSOKCs (75.0%) and SOKCs
(45.5%) showed a RANKL = OPG ratio. No statistically significant
differences were observed between groups (P = 0.061) (Table 2).
3.2. Angiogenic index
Immunohistochemical reactivity for CD34 was detected in
endothelial cells of vessels with distinct lumens, as well as in
Fig. 1 – (a) Expression of RANKL in the epithelial lining (score 3) and in cells (arrows) of the fibrous capsule of SOKC (LSAB,
T400). (b) Expression of RANKL in the epithelial lining (score 1) of primary NSOKC (LSAB, T400). (c) Expression of OPG in the
epithelial lining (score 1) of SOKC (LSAB, T400). (d) Expression of OPG in the epithelial lining (score 3) and in cells (arrows) of
the fibrous capsule of primary NSOKC (LSAB, T400). (e) Vessels immunoreactive to anti-CD34 antibody (arrows) in SOKC,
most of them exhibiting small lumen (LSAB, T100). (f) Variably sized vessels immunoreactive to anti-CD34 antibody
(arrows) in recurrent NSOKC (LSAB, T100). (g) Presence of myofibroblasts (arrows) in the fibrous capsule of SOKC (LSAB,
T400). (h) Presence of myofibroblasts (arrows) in the fibrous capsule of primary NSOKC (LSAB, T400).
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Table 2 – Distribution of cases of primary non-syndrome OKCs, recurrent non-syndrome OKCs, and syndrome OKCs
according to the RANK/OPG ratio in the epithelial lining and in the fibrous capsule.
Location/group RANKL/OPG ratio P
RANKL > OPG
n (%)
RANKL < OPG
n (%)
RANKL = OPG
n (%)
Epithelial lining
Primary non-syndrome OKC 1 (4.5) 12 (54.5) 9 (40.9) 0.573
Recurrent non-syndrome OKC 1 (12.5) 4 (50.0) 3 (37.5)
Syndrome OKC 2 (9.1) 7 (31.8) 13 (59.1)
Fibrous capsule
Primary non-syndrome OKC 1 (4.5) 3 (13.6) 18 (81.8) 0.061
Recurrent non-syndrome OKC 2 (25.0) 0 (0.0) 6 (75.0)
Syndrome OKC 5 (22.7) 7 (31.8) 10 (45.5)
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lumen. The mean number of blood vessels determined by MVC
was 71.6 (range: 52.4–107.2) in SOKCs (Fig. 1e) and 69.2 (range:
47.0–108.0) in primary NSOKCs. In recurrent NSOKCs, the
mean number of blood vessels was 67.6 (range: 34.0–104.4)
(Fig. 1f). The nonparametric Kruskal–Wallis test revealed no
significant differences between groups (P = 0.809).
Spearman’s correlation test revealed no significant corre-
lation between the angiogenic index and the expression of
RANKL or OPG in the epithelial lining (P > 0.05) and fibrous
capsule (P > 0.05) of all groups of OKCs.
3.3. Myofibroblasts
Analysis of the immunohistochemical expression of anti-a-
SMA antibody showed the presence of myofibroblasts in all
groups of OKCs. The mean number of myofibroblasts was 33.7
(range: 20.5–56.7) in SOKCs (Fig. 1g) and 34.4 (range: 17.9–53.2)
in primary NSOKCs (Fig. 1h). In recurrent NSOKCs, the mean
number of myofibroblasts was 29.3 (range: 11.7–44.6). The
nonparametric Kruskal–Wallis test showed no significant
differences between groups (P = 0.590).
For all groups, Spearman’s correlation test showed no
significant correlation between the number of myofibroblasts
and the angiogenic index (P > 0.05).
4. Discussion
SOKCs and NSOKCs have been suggested to share a common
pathogenesis, which is characterised by mutations in the PTCH
gene and consequent aberrant activation of the SHH signalling
pathway.31,32 Despite these studies, SOKCs have been reported
to present a greater growth and infiltration capacity4 and a
higher tendency to recur5,6 than NSOKCs. Accordingly, the
results of several investigations support the existence of a
distinct biological behaviour of SOKCs and NSOKCs.4,7–10
The molecular triad RANK, RANKL and OPG is critical for
the control of osteoclastogenesis and pathophysiological bone
remodelling.18 Binding of RANKL to RANK leads to preosteo-
clast recruitment, fusion into multinucleate osteoclasts,
osteoclast activation, and osteoclast survival.17 On the other
hand, OPG suppresses bone resorption by inhibiting the
interaction between RANK and RANKL.17,18 Alterations in
the balance between RANKL and OPG play a pivotal role inseveral osteolytic diseases18,33 and may be due to an increase
in the concentration of RANKL or a decrease in the
concentration of OPG or both.16,34
On the basis of these findings, elevated reactivity for
RANKL when compared to OPG would be expected in
odontogenic cysts and tumours. Coherently, higher expres-
sion of RANKL compared to OPG has been demonstrated in
solid ameloblastomas,12 calcifying epithelial odontogenic
tumours, odontogenic myxomas, and ameloblastic fibro-
mas.11 According to Andrade et al.11 and da Silva et al.12
these findings are consistent with the aggressive clinical
behaviour of solid ameloblastomas and with the potential for
recurrence and bone resorption of odontogenic myxomas and
ameloblastic fibromas.
In the present study, analysis of the RANKL/OPG ratio in the
epithelial lining and fibrous capsule revealed a RANKL = OPG
ratio or RANKL < OPG ratio in most NSOKCs and SOKCs
(P > 0.05), suggesting that differences in the biological behav-
iour of these lesions may not be related to this ratio. In
agreement with these results, da Silva et al.12 observed that
sporadic OKCs tend to present RANKL = OPG ratios in the
epithelial lining and RANKL < OPG ratios in the fibrous
capsule. According to Andrade et al.11 odontogenic lesions
that are cystic in architecture but neoplastic in nature (e.g.,
unicystic ameloblastoma, and calcifying cystic odontogenic
tumour) tend to present a lower RANKL/OPG ratio than solid
tumours, a finding that might be related to the osteolytic
potential of these lesions.
Nevertheless, in view of the potentially aggressive biologi-
cal behaviour of OKCs,3,32 the consistent expression of OPG in
OKCs observed in the present study suggests the involvement
of this protein in biological processes other than bone
remodelling. In line with this suggestion, Sandra et al.35
showed that treatment of an ameloblastoma-derived cell line
with OPG significantly reduced the potential of tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL) to
induce apoptosis in these cells. These findings suggest that the
expression of OPG in OKCs might be related to an antiapoptotic
role of this protein in these lesions, particularly in the
epithelial lining.
Studies have also demonstrated the involvement of RANKL
and OPG in vascular biology, with these proteins being able to
stimulate the survival, proliferation and migration of endo-
thelial cells.18–20 However, the present results showed no
significant correlation between the angiogenic index and
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proteins may not be involved in the formation of new blood
vessels in OKCs.
Angiogenesis is a complex process that is regulated by
several intercellular pathways that exert both pro- and anti-
angiogenic functions.21,36 This process, which can be evaluat-
ed by determination of the angiogenic index, is critical for the
development and progression of odontogenic cysts and
tumours.13,29,37 In addition, studies have shown a relationship
between the angiogenic index and biological behaviour of
odontogenic lesions.13,37 In this respect, Alaeddini et al.13
observed that microvessel density (MVD) is higher in solid
ameloblastomas than in OKCs and dentigerous cysts, suggest-
ing that angiogenesis is one of the mechanisms contributing to
the different biological behaviours of these lesions. Similarly,
Chen et al.37 found a gradient in the vascularisation of OKCs,
primary ameloblastomas, recurrent ameloblastomas, and
malignant ameloblastomas, with lower MVD counts in OKCs
and higher counts in malignant ameloblastomas. In the
present study, no significant differences in the MVC were
observed between NSOKCs and SOKCs (P > 0.05), indicating
that differences in the biological behaviour of these lesions are
not related to the angiogenic index.
Recently, Mitrou et al.38 demonstrated a linear relationship
between the expression of vascular endothelial growth factor
(VEGF) and cell proliferation in the epithelial lining of OKCs.
According to these authors, the expression of this proangio-
genic factor by epithelial cells of OKCs might promote growth
through an autocrine proliferative effect on the cystic
epithelium. A similar proliferative effect has been demon-
strated in biliary cysts developing in acquired dominant
polycystic kidney disease.39 Taken together, these findings
and the present results regarding the angiogenic index of
SOKCs and NSOKCs highlight the importance of further
studies investigating the non-angiogenic functions of VEGF
in OKCs.
Myofibroblasts are specialised contractile cells that have
been implicated in a variety of diseases, such as fibrocon-
tractive diseases and cancer, due to their ability to synthesise
extracellular matrix components and to secrete proteases,
cytokines and proangiogenic factors.24–26 With respect to
odontogenic lesions, Vered et al.14 observed that the mean
number of myofibroblasts was significantly higher in solid
ameloblastomas and OKCs than in dentigerous cysts, uni-
cystic ameloblastomas, and ameloblastic fibromas/fibro-
odontomas. According to these authors, myofibroblasts may
contribute to the biological behaviour of aggressive odonto-
genic lesions. Recently, Fregnani et al.15 showed that both the
abundant presence of myofibroblasts and the expression of
matrix metalloproteinase-2 (MMP-2) in solid ameloblastomas
were significantly associated with rupture of cortical bone.
In the present study, myofibroblasts were detected in the
fibrous capsule of primary NSOKCs, recurrent NSOKCs, and
SOKCs. These findings agree with previous studies indicating
these cells to be an important component of the fibrous
capsule of OKCs.14,40 However, analysis of the number of a-
SMA-positive cells revealed no significant differences between
groups (P > 0.05), suggesting that differences in the biological
behaviour of SOKCs and NSOKCs may not be related to the
number of myofibroblasts in these lesions.Nevertheless, the possibility of quantitative and/or quali-
tative differences in the products synthesised by myofibro-
blasts in SOKCs and NSOKCs cannot be ruled out. This
suggestion is supported by studies investigating the expres-
sion of MMPs. Cavalcante et al.9 observed a higher expression
of MMP-1 in the fibrous capsule of SOKCs when compared to
NSOKCs. In addition, Leonardi et al.10 showed strong immu-
noreactivity for MMP-13 in the fibrous capsule of SOKCs,
whereas no expression of this protease was observed in
NSOKCs. Studies have demonstrated that myofibroblasts
constitute an important source of proteases such as MMPs-
1, -2, -3, -9, and -13.15,26,41,42 In this respect, the similar number
of myofibroblasts in syndrome and non-syndrome OKCs
observed in the present investigation suggests that the
differences in the expression of MMP-1 and MMP-13 reported
in the studies of Cavalcante et al.9 and Leonardi et al.10 may be
partially related to differences in the synthesis capacity of
myofibroblasts present in SOKCs and NSOKCs.
Myofibroblasts have been shown to play an important
role in tumour angiogenesis. Konstantinopoulos et al.43
demonstrated that myofibroblasts surrounding colon ade-
nocarcinomas are an important source of VEGF and
cyclooxygenase-2, two well-recognised proangiogenic fac-
tors. Using a gastric cancer mouse model, Guo et al.44
observed that myofibroblasts stimulated by tumour cells
express VEGF-A and other angiogenic factors, promoting
angiogenesis. However, no significant correlation was found
between the number of myofibroblasts and angiogenic index
in the present study (P > 0.05). Therefore, myofibroblasts
may not be primarily involved in the formation of new blood
vessels in OKCs.
The present results suggest that differences in the
biological behaviour of SOKCs and NSOKCs may not be related
to the expression of RANKL and OPG, to the RANKL/OPG ratio,
to the angiogenic index, or to the number of myofibroblasts in
these lesions. In view of the lack of differences in the
angiogenic index and in the number of myofibroblasts
between these lesions, studies investigating possible qualita-
tive differences in vascularisation and in the products
synthesised by myofibroblasts, such as growth factors and
proteases, may help explain the increased aggressiveness of
OKCs related to Gorlin syndrome.
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